Literature DB >> 28003217

The Early Clinical Response Endpoint: Great Timing by the Food and Drug Administration?

George H Talbot1.   

Abstract

Keywords:  acute bacterial skin and skin structure infection (ABSSSI); antibiotic development; clinical trial endpoints; community-acquired bacterial pneumonia (CABP); noninferiority trials.

Mesh：

Year:  2016        PMID： 28003217     DOI： 10.1093/cid/ciw752

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  2 in total

1.  Efficacy and Safety of Tedizolid Phosphate versus Linezolid in a Randomized Phase 3 Trial in Patients with Acute Bacterial Skin and Skin Structure Infection.

Authors:  Xiaoju Lv; Jeff Alder; Li Li; William O'Riordan; Michael J Rybak; Hui Ye; Ruiping Zhang; Zhongqi Zhang; Xu Zhu; Mark H Wilcox
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

2.  Post Hoc Assessment of Time to Clinical Response Among Adults Hospitalized with Community-Acquired Bacterial Pneumonia Who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials.

Authors:  Thomas Lodise; Sam Colman; Daniel S Stein; David Fitts; Lisa Goldberg; Elizabeth Alexander; Patrick J Scoble; Jennifer Schranz
Journal:  Open Forum Infect Dis       Date:  2020-04-24       Impact factor: 3.835
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.